ArticleScientific reports2025
Molecular insights into antibiofilm inhibitors of Streptococcus mutans glucosyltransferases through in silico approaches.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Transposon mutant library reveals the complex regulatory network of biofilm formation inBiofilm · 2026Article
- In Silico Identification of Dual-Action Compounds Targeting TLR2 andDentistry journal · 2026Article
- Therapeutic Potential and Sustainable Bioprocessing of Enterocin CC2: A Probiotic-Derived Antimicrobial Targeting Streptococcus mutans in Oral Health.Probiotics and antimicrobial proteins · 2026Article
- Mechanisms of caries induced by sugars: a narratives review from microbial metabolism to oral ecological imbalance and public health strategies for caries prevention.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptococcus mutans, a primary cariogenic bacterium, plays a central role in dental caries, one of the most widespread chronic diseases globally. Glucosyltransferases (GTFs) are key virulence factors in this process, as they synthesize extracellular polysaccharides that contribute to biofilm formation and pathogenicity. Targeting GTFs has emerged as a promising strategy for preventing dental caries, with previous studies demonstrating its potential efficacy. This study builds on our prior work by providing detailed molecular insights into the binding modes of previously identified GTF inhibitors. Using computational tools, including density functional theory, molecular docking, and molecular dynamics simulations, we examined the binding interactions and structural stability of selected inhibitors. All investigated candidates demonstrated superior binding behavior compared to the reference ligand, acarbose, as indicated by multiple structural parameters. Structural dynamics analysis revealed significant stability in the binding interactions of Complex III and V, with average deviations of 2.06 ± 0.38 and 2.07 ± 0.30 Å, respectively. Similarly, a trend in structural compactness was observed, with gyration values of 32.98 ± 0.23 and 33.01 ± 0.24 Å, respectively. Principal component analysis indicated that the constructed pattern approaches zero with the achievement of a global energy minimum, particularly for Complex III and V. Furthermore, MM/PBSA free energy calculations identified Compound V as the most favorable binder, with a binding free energy of -24.20 kcal/mol. Our findings provide valuable molecular-level insights into the inhibitory mechanisms of GTF-targeting compounds, strengthening their potential as anti-cariogenic agents. By elucidating key binding interactions, this study contributes to the ongoing search for improved scaffolds that may hinder biofilm-mediated infections and advance therapeutic strategies against dental caries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.